EP2945649A1 - Composition and uses thereof - Google Patents
Composition and uses thereofInfo
- Publication number
- EP2945649A1 EP2945649A1 EP14707429.8A EP14707429A EP2945649A1 EP 2945649 A1 EP2945649 A1 EP 2945649A1 EP 14707429 A EP14707429 A EP 14707429A EP 2945649 A1 EP2945649 A1 EP 2945649A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- sequence
- particle
- fusion protein
- composition
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 74
- 239000002245 particle Substances 0.000 claims abstract description 121
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 67
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 67
- 102000036639 antigens Human genes 0.000 claims abstract description 50
- 108091007433 antigens Proteins 0.000 claims abstract description 50
- 239000000427 antigen Substances 0.000 claims abstract description 41
- 241000223960 Plasmodium falciparum Species 0.000 claims abstract description 40
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 36
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 33
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 29
- KQPKMEYBZUPZGK-UHFFFAOYSA-N 4-[(4-azido-2-nitroanilino)methyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol Chemical group CC1=NC=C(CO)C(CNC=2C(=CC(=CC=2)N=[N+]=[N-])[N+]([O-])=O)=C1O KQPKMEYBZUPZGK-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000002671 adjuvant Substances 0.000 claims description 51
- 238000002649 immunization Methods 0.000 claims description 42
- 229960005486 vaccine Drugs 0.000 claims description 41
- 239000013603 viral vector Substances 0.000 claims description 32
- 201000004792 malaria Diseases 0.000 claims description 30
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 29
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 28
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims description 27
- 230000028993 immune response Effects 0.000 claims description 22
- 239000013598 vector Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 101001111984 Homo sapiens N-acylneuraminate-9-phosphatase Proteins 0.000 claims description 14
- 102100023906 N-acylneuraminate-9-phosphatase Human genes 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 230000001681 protective effect Effects 0.000 claims description 12
- 108020004414 DNA Proteins 0.000 claims description 11
- 241000235058 Komagataella pastoris Species 0.000 claims description 11
- 206010035500 Plasmodium falciparum infection Diseases 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 101710137302 Surface antigen S Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 241000320412 Ogataea angusta Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 description 36
- 241000699670 Mus sp. Species 0.000 description 34
- 235000018102 proteins Nutrition 0.000 description 25
- 230000004044 response Effects 0.000 description 25
- 102100031675 DnaJ homolog subfamily C member 5 Human genes 0.000 description 24
- 210000001744 T-lymphocyte Anatomy 0.000 description 24
- 238000011725 BALB/c mouse Methods 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 22
- 230000005847 immunogenicity Effects 0.000 description 22
- 238000002965 ELISA Methods 0.000 description 21
- 229940024606 amino acid Drugs 0.000 description 20
- YYGNTYWPHWGJRM-AAJYLUCBSA-N squalene Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC=C(C)C YYGNTYWPHWGJRM-AAJYLUCBSA-N 0.000 description 19
- 230000005875 antibody response Effects 0.000 description 16
- 230000002163 immunogen Effects 0.000 description 16
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 241001217856 Chimpanzee adenovirus Species 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 10
- 244000045947 parasite Species 0.000 description 10
- 210000003046 sporozoite Anatomy 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
- 230000005867 T cell response Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 229930182490 saponin Natural products 0.000 description 7
- 150000007949 saponins Chemical class 0.000 description 7
- 235000017709 saponins Nutrition 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 208000009182 Parasitemia Diseases 0.000 description 6
- 208000030852 Parasitic disease Diseases 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 229940124735 malaria vaccine Drugs 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 229910052709 silver Inorganic materials 0.000 description 4
- 239000004332 silver Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
- 101150106931 IFNG gene Proteins 0.000 description 3
- 241000224017 Plasmodium berghei Species 0.000 description 3
- 101800004937 Protein C Proteins 0.000 description 3
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 description 3
- 101800001700 Saposin-D Proteins 0.000 description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229960000856 protein c Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 229940031439 squalene Drugs 0.000 description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 101150052200 CS gene Proteins 0.000 description 2
- 101710117490 Circumsporozoite protein Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004147 Sorbitan trioleate Substances 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940001442 combination vaccine Drugs 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- VIYFPAMJCJLZKD-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate Chemical compound [Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 VIYFPAMJCJLZKD-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000019337 sorbitan trioleate Nutrition 0.000 description 2
- 229960000391 sorbitan trioleate Drugs 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- -1 Abisco Substances 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101710194180 Alcohol oxidase 1 Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000002476 Falciparum Malaria Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 101100494726 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pep-4 gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 241001417521 Pomacentridae Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000013406 biomanufacturing process Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960000106 biosimilars Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 125000001909 leucine group Chemical class [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940118768 plasmodium malariae Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940038774 squalene oil Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940023147 viral vector vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
- C07K16/205—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to immunogenic compositions for use in eliciting immune responses to pathogenic organisms, and in particular, for the prevention of malaria.
- the invention also provides for the use of the immunogenic compositions, in particular, for use in eliciting a protective immune response.
- Plasmodium falciparum malaria is one of the major infectious diseases of centuries. It is the most important parasitic cause of human mortality and a major cause of death in young African children. Current estimates of annual deaths from malaria vary from about 700,000 to over a million. Most of this mortality is in Africa. Additionally there are about 250 million clinical cases of malaria each year, providing a huge burden of morbidity that adds to the disease burden caused by malaria deaths. Although current control measures, such as bed nets, insecticide spraying and rapid drug treatments are partially effective it is widely considered important to develop new tools to control malaria. Probably the most useful of these tools would be an effective malaria vaccine.
- the RTS,S vaccine was developed by GSK Biologicals from 1988 to an ongoing phase III trial in African children. This vaccine induces high antibody responses that bind to the major surface component of the malaria sporozoite, the circumsporozoite protein (CS protein), and thereby prevent or reduce parasite entry into the liver (Kester, K.E., et al. J Infect Dis 200, 337-346, 2009).
- the vaccine is an unusual construct. It comprises a fusion protein of most of the circumsporozoite protein fused at the gene level to the DNA encoding the surface antigen of hepatitis B (HBsAg).
- RTS hepatitis B surface antigen
- An aim of the present invention is to provide an alternative immunogen for use in the prevention of malaria, wherein the efficacy of the immunogen is preferably greater than RTS,S.
- the invention provides a particle comprising a fusion protein comprising at least one NANP repeat, some or all of the C-terminus of the CS protein from Plasmodium falciparum and a hepatitis B surface antigen.
- the hepatitis B surface antigen is the S antigen.
- the NANP repeat is a repeat of the four amino acids asparagine, alanine, asparagine, proline which occurs naturally in the CS protein from Plasmodium falciparum. There may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or more repeats ofNANP. Preferably there are at least 3 repeats, more preferably there are at least 10 repeats.
- the fusion protein may in one embodiment comprise 18 repeats ofNANP.
- the C-terminus of the CS protein is often referred to as the T-cell epitope containing C- terminus.
- the C-terminus of the CS protein included in the fusion protein of the invention may comprise the sequence:
- the C-terminus of the CS protein in the fusion protein may have the sequence:
- the particle of the invention is sometimes referred to as a virus-like particle. It is considered that such particles are more immunogenic than monomelic proteins.
- the particle may comprise no, or substantially no, other proteinaceous material.
- the particle of the invention may comprise no, or substantially no, free hepatitis B surface antigen protein: that is no, or substantially no, hepatitis B surface antigen protein which is not part of the fusion protein.
- the particle of the invention may comprise no, or substantially no, free CS protein: that is no, or substantially no, CS protein which is not part of the fusion protein.
- the particle preferably requires the particle to comprise less than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or about 1% of the particular material referred.
- the particles Preferably contain less than 5%, more preferably less than 1%, free hepatitis B surface antigen protein.
- a particle of the invention at least about 40% or more by mass of the proteinaceous material is derived from Plasmodium falciparum.
- Plasmodium falciparum material in the particles allows a more favourable antibody response with respect to malaria, more specifically a significantly improved antibody response to Plasmodium falciparum is observed with particles of the invention, and a smaller antibody response is seen to the hepatitis B surface antigen.
- a reduction in the relative amount of hepatitis B surface antigen in the particles may also have the advantage that the particles have improved efficacy in early infancy. If too much hepatitis B surface antigen is present there is concern that maternal antibodies present in a young infant may make the particles less effective as immunogens.
- the hepatitis B surface antigen is C-terminal to any Plasmodium falciparum material.
- the particle may comprise a fusion protein comprising, or consisting of, the sequence of Seq ID No: 1 (R21) or a sequence with at least 80%, 85%, 90%, 95%, 98%, 99% or more sequence identity with the sequence of Seq ID No: 1.
- Percentage sequence identity is defined as the percentage of amino acids in a sequence that are identical with the amino acids in a provided sequence after aligning the sequences and introducing gaps if necessary to achieve the maximum percent sequence identity. Alignment for the purpose of determining percent sequence identity can be achieved in many ways that are well known to the man skilled in the art, and include, for example, using BLAST (National Center for Biotechnology Information Basic Local Alignment Search Tool). Variations in percent identity may be due, for example, to amino acid substitutions, insertions or deletions. Amino acid substitutions may be conservative in nature, in that the substituted amino acid has similar structural and/or chemical properties, for example the substitution of leucine with isoleucine is a conservative substitution.
- a sequence of Seq ID No: 1 includes sequences with conservative substitutions which do not have any significant effect on the immunogenicity of the resulting fusion protein. Substitutions may also be introduced to match better the CS sequence of other strains of Plasmodium falciparum.
- the sequence used in the R21 example reported here is of the 3D7 strain.
- the particle may comprise, or consist of, a fusion protein having the sequence of Seq ID No: 2 (RTS) or having a sequence with at least 80%, 85%, 90%, 95%, 98%, 99% or more sequence identity with the sequence of Seq ID No: 2, wherein the particle does not comprise any, or substantially any, hepatitis B surface antigen protein which is not part of the fusion protein.
- RTS Seq ID No: 2
- the particle may comprise, or consist of, a fusion protein having the sequence of Seq ID No: 2 (RTS) or having a sequence with at least 80%, 85%, 90%, 95%, 98%, 99% or more sequence identity with the sequence of Seq ID No: 2, wherein the particle does not comprise any, or substantially any, CS protein which is not part of the fusion protein.
- a particle of the invention comprises numerous monomers of the fusion protein.
- the particle may comprise a least 10 fusion protein monomers, preferably 20 or more, 30 or more, 40 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, 100 or more fusion protein monomers.
- the particle comprises around 96 fusion protein monomers.
- a particle of the invention is immunogenic.
- a particle of the invention may be capable of eliciting an immune response against the malaria causing parasite Plasmodium falciparum.
- the immune response may be therapeutic and/or prophylactic.
- the immune response may be sufficient to reduce or prevent infection or disease cause by Plasmodium falciparum.
- the particle may elicit/produce a protective immune response when administered to a subject, preferably a human subject.
- the immune response elicited by the composition of the invention affects the ability of Plasmodium falciparum to infect an immunised human.
- the ability of Plasmodium falciparum to infect a human immunised with the composition of the invention is impeded or prevented.
- the immune response elicited may recognise and destroy Plasmodium falciparum. Alternatively, or additionally, the immune response elicited may impede or prevent replication of Plasmodium falciparum. Alternatively, or additionally, the immune response elicited may impede or prevent Plasmodium falciparum causing disease in the human or non-human animal. Preferably the immune response elicited is an antibody response.
- the particle may be provided in a liquid formulation. Alternatively, the particle may be provided in a lyophilised form. Alternatively the particle may be provided in a sugar based formulation dried on membranes as described by Alcock et al. (Sci Transl Med.
- the invention provides a method of producing particles according to the first aspect of the invention comprising expressing the fusion protein in Saccharomyces cerevisiae or Pichia pastoris or another methylotrophic yeast such as Hansenula polymorpha and recovering the fusion protein, preferably in the form of particles. If the fusion protein is expressed in Pichia pastoris, or another methylotrophic yeast, expression of the protein may be driven by the AOXl promoter or by the GAP promoter or by another strong promoter (Vogl & Glieder, New Biotechnology. 2012 Nov 16. pii: S 1871- 6784(12)00867-9).
- fusion protein is expressed in Saccharomyces cerevisiae
- expression of the protein may be driven by the TDH3 promoter or by another strong promoter.
- the fusion protein is expressed at sufficiently high levels that upon lysis of the yeast the fusion proteins spontaneously multimerise to form particles, sometime referred to as viruslike particles.
- the DNA encoding the fusion protein may be transiently or constitutively expressed by the yeast.
- the DNA encoding the fusion protein may be integrated into the host genome or may be carried on an extracellular component, such as a plasmid.
- the yeast may contain, 1, 2, 3, 4, 5 or more copies of the DNA encoding the fusion protein.
- the DNA encoding the fusion protein may be codon optimised for expression in yeast.
- a person skilled in the art would be readily able to prepare a suitable host to express the DNA encoding the fusion protein.
- Saccharomyces cerevisiae or Pichia pastoris or another methylotrophic yeast used in the method of the invention does not express any, or any significant, hepatitis B surface antigen protein which is not part of the fusion protein.
- Saccharomyces cerevisiae or Pichia pastoris or another methylotrophic yeast used in the method of the invention does not express any, or any significant, CS protein from Plasmodium falciparum which is not part of the fusion protein.
- the ability to express particles according to the invention in a high yielding yeast strain, such as Pichia pastoris, may simplify and enhance the biomanufacture of the particles leading to lower cost of goods for manufacture. This saving in cost is particularly important for a malaria vaccine which is targeted primarily at populations, especially children and infants, in low income countries who require a low cost vaccine.
- the invention provides a particle produced by the method of the invention.
- the invention provides a host Saccharomyces cerevisiae or Pichia pastoris or another methylotrophic yeast cell comprising a polynucleotide, such as DNA, encoding for the fusion protein referred to with reference to the particle of the invention.
- the invention provides a Saccharomyces cerevisiae or Pichia pastoris or another methylotrophic yeast cell comprising DNA encoding a fusion protein comprising, or consisting of, the sequence of Seq ID No: 1 (R21) or a sequence with at least 80%, 85%, 90%, 95%, 98%, 99% or more sequence identity with the sequence of Seq ID No: 1.
- Preferably expression of the DNA is driven by the AOX 1 promoter.
- the invention provides a DNA sequence encoding a fusion protein referred to with reference to the particle of the invention.
- the invention may also provide a vector containing the DNA sequence, wherein the DNA sequence may be operably linked to transcriptional control elements.
- the invention provides a composition
- a composition comprising i) a fusion protein comprising at least one NANP repeat, some or all of the C-terminus of the CS protein from Plasmodium falciparum and a hepatitis B surface antigen; and ii) a recombinant or non- recombinant viral vector.
- the viral vector may express an antigen.
- the viral vector may be a modified vaccinia virus Ankara (MVA).
- the viral vector may encode TRAP and/or ME-TRAP.
- the antigen expressed by the viral vector may another malaria antigen, such as for example CSP.
- composition may further comprise an adjuvant.
- the adjuvant may contain saponin and may be Abisco, matrix M, QS21, AS01 or AS02.
- the composition may in part i) comprise the fusion protein as a particle as described herein.
- the composition may comprise in part i) the fusion protein RTS, and may further comprise free S antigen from hepatitis B.
- the invention provides a pharmaceutical composition, and in particular a vaccine composition for use in the prevention of malaria, comprising the particles or composition of the invention and a pharmaceutically acceptable carrier or excipient.
- Suitable acceptable excipients and carriers will be well known to those skilled in the art. These may include solid or liquid carriers. Suitable liquid carriers include water and saline.
- the proteins of the composition may be formulated into an emulsion or they may be formulated into biodegradable microspheres or liposomes.
- the composition may further comprise an adjuvant.
- Suitable adjuvants will be well known to those skilled in the art, and may include Freund's Incomplete Adjuvant (for use in animals), a saponin derivative, an emulsion such as MF59, and metal salts such as aluminium or calcium salts, for example alum.
- the adjuvant may be a squalene-based adjuvant, such as AddaVax (Invivogen) and/or an ISCOM-based adjuvant, such as Abisco/Matrix M (from Isconova), and/or MF59 (Novartis, Siena, Italy).
- AddaVaxTM is based on nano-emulsification of 2 components: Sorbitan trioleate (0.5% w/v) in squalene oil (5% v/v); and Tween 80 (0.5% w/v) in sodium citrate buffer (10 mM, pH 6.5).
- Sorbitan trioleate (0.5% w/v) in squalene oil (5% v/v); and Tween 80 (0.5% w/v) in sodium citrate buffer (10 mM, pH 6.5).
- the nano-emulsion is produced using a microfluidizer and filtered through a 0.22- ⁇ filter to remove large droplets and sterilize the final product.
- the particle size is ⁇ 160 nm.
- MF59 is a ⁇ 160 run particle emulsion (Novartis, Siena) comprising Squalene: 9.75 mg; Polysorbate 80: 1.175 mg; Sorbitan trioleate: 1.175 mg; Sodium citrate: 0.66 mg; Citric acid: 0.04 mg.
- Abisco-100 (known as Matrix-M when made to GMP standard) has the following chemical content: purified saponins obtained from a crude extract of the plant Quillaja saponaria Molina; cholesterol from Lanolin and phosphatidyl choline (phospholipid) from fresh egg yolk; in a suspension of nano-sized (40nm) cage-like particles consisting of the above ingredients, in PBS.
- Matrix M (or Abisco-100) consists of a mixture of Matrix A and Matrix C at a ratio of 80:20 to 95:5, preferably 85: 15.
- Matrix A leads to T cell induction and has low toxicity
- Matrix C induces antibodies and has some toxicity.
- Matrix C contains C fraction of QS separation which corresponds to QS21. Fraction A (in Matrix A) corresponds to QS7.
- composition may also comprise polymers or other agents to control the consistency of the composition, and/or to control the release of the antigen/secreted protein from the composition.
- composition may also comprise other agents such as diluents, which may include water, saline, glycerol or other suitable alcohols etc; wetting or emulsifying agents; buffering agents; thickening agents for example cellulose or cellulose derivatives; preservatives; detergents, antimicrobial agents; and the like.
- diluents which may include water, saline, glycerol or other suitable alcohols etc; wetting or emulsifying agents; buffering agents; thickening agents for example cellulose or cellulose derivatives; preservatives; detergents, antimicrobial agents; and the like.
- the active ingredients in the composition are greater than 50% pure, usually greater than 80% pure, often greater than 90% pure and more preferably greater than 95%, 98% or 99% pure. With active ingredients approaching 100% pure, for example about 99.5% pure or about 99.9% pure, being used most often.
- composition of the invention may also include in admixture one or more further antigens.
- the one or more further antigens may be derived from Plasmodium falciparum or from other species of Plasmodium, such as Plasmodium vivax or Plasmodium malariae.
- the pharmaceutical composition or vaccine composition may be provided in a liquid form or in a lyophilised form.
- the pharmaceutical composition or vaccine composition may be intended for administration in a dose selected to give an appropriate immune response whilst not causing significant side affects.
- Each dose may comprise between about 1 and about 1000 ⁇ g of fusion protein, for example between about 1 and about 200 ⁇ g of fusion protein, preferably between about 1 and about 50 ⁇ g of fusion protein.
- the optimal amount of particles/fusion protein to be used can be ascertained by standard studies well known to a person skilled in the art.
- the pharmaceutical composition or vaccine composition is capable of producing a protective immune response to Plasmodium falciparum.
- the phrase "producing a protective immune response" as used herein means that the composition is capable of generating a protective response in a host organism, such as a human or a non-human mammal, to whom it is administered.
- a protective immune response protects against subsequent infection or disease caused by Plasmodium falciparum.
- the protective immune response may eliminate or reduce the level of infection by reducing replication of Plasmodium falciparum or by affecting the mode of action of Plasmodium falciparum to reduce disease.
- the composition comprises an immunologically effective amount of particles according to the invention.
- An "immunologically effective amount" of an antigen is an amount that when administered to an individual, either in a single dose or in a series of doses, such as 2 to 4 doses, is effective for treatment or prevention of infection by Plasmodium falciparum. This amount will vary depending upon the health and physical condition of the individual to be treated and on the antigen. Determination of an effective amount of an immunogenic or vaccine composition for administration to an organism is well within the capabilities of those skilled in the art.
- a composition according to the invention may be for oral, systemic, parenteral, topical, mucosal, intramuscular, intravenous, intraperitoneal, intradermal, subcutaneous, intranasal, intravaginal, intrarectal, transdermal, sublingual, inhalation or aerosol administration.
- the composition may be arranged to be administered as a single dose or as part of a multiple dose schedule. Multiple doses may be administered as a primary immunisation followed by one or more booster immunisations. Suitable timings between priming and boosting immunisations can be routinely determined, but will typically be at intervals of 2 weeks to 4 months.
- compositions of the invention may be able to induce serum antibody responses which mediate the destruction or inactivation of the Plasmodium falciparum after being administered to a subject. These responses are conveniently measured in mice and the results are a standard indicator of vaccine efficacy.
- compositions of the invention may also, or alternatively, be able to elicit an immune response which neutralises Plasmodium falciparum, thereby preventing them from having their normal function and preventing or reducing disease progression without necessarily destroying the Plasmodium falciparum.
- a composition according to the invention may be used in isolation, or it may be combined with one or more other immunogenic or vaccine compositions, and/or with one or more other therapeutic regimes.
- the composition may be intended for administration with a viral vector.
- the viral vector may encode one or more pre-erythrocytic malaria antigens or antigens from other stages of the malaria parasite's life-cycle.
- the antigen encoded may be the malarial antigen TRAP (thrombospondin related adhesion protein) or ME-TRAP.
- TRAP thrombospondin related adhesion protein
- ME-TRAP thrombospondin related adhesion protein
- the strong T cell immunogenicity of such vectored vaccines that are known to have some partial efficacy against the liver-stage of malaria infection, is either maintained or even, surprisingly, enhanced when combined with a composition of the invention.
- the invention may provide a combination malaria vaccine, comprising particles according to the invention and a viral vector. The combination would have potent anti-sporozoite activity primarily induced by the particles and anti-liver-stage activity primarily induced by the viral vectors.
- the composition may be intended to be administered with one or more of an adenovirus vector and an MVA vector.
- the composition may be administered in a prime boost regimen, wherein the prime comprises the particles of the invention and an adenovirus vector or an MVA vector, and the boost comprises the particles of the invention and adenovirus or an MVA vector.
- the prime comprises an adenovirus
- boost comprises an MVA vector.
- the prime and the boost include an adjuvant with the particles.
- the adenoviral vector or the MVA viral vectors and the particles of the invention may be administered as a mixture, or alternatively they may be administered separately, meaning at separate immunisation sites or at separate time points. If administered separately the vector and particles may be administered at the same or different sites.
- vector and particles may be simultaneous, or substantially simultaneous, for example, within 10 minutes of each other, or the administration may be sequential.
- the vector and particles are administered sequentially, they are administered within at most about 30 days, 7 days, 6 days, 4 days, 2 days, 24 hours or less, of each other.
- composition of the invention may further comprise one or more viral vectors.
- the invention provides a fusion protein comprising the sequence of Seq ID No: 1 (R21) or comprising, or consisting of, a sequence with at least 80%, 85%, 90%, 95%, 98%, 99% or more sequence identity with the sequence of Seq ID No: 1.
- the fusion protein consists of the sequence of Seq ID No: 1 (R21).
- the invention provides a method of treating a subject susceptible to Plasmodium falciparum infection comprising administering to the subject an effective amount of a pharmaceutical composition or vaccine composition according to the invention.
- the invention provides a method of immunising a subject against malaria/ 'Plasmodium falciparum infection comprising administering to the subject an effective amount of a pharmaceutical composition or vaccine composition according to the invention.
- the invention provides a use of a pharmaceutical composition or vaccine composition according to the invention in the preparation of a medicament for the treatment/immunisation of a subject susceptible to Plasmodium falciparum infection.
- the invention provides a pharmaceutical composition or vaccine composition according to the invention for use in the treatment/immunisation of a subject susceptible to Plasmodium falciparum infection.
- the invention provides a kit for use in inducing an immune response to Plasmodium falciparum comprising a particle or composition according to the invention and instructions relating to administration.
- the kit may further comprise one or more of an adjuvant and a viral vector. If an adjuvant is present preferably it is in the same composition as the particle.
- the viral vector may be in a same of different composition to the particle.
- Figure 1 provides the sequence of R21 (Seq ID No: 1) and RTS (Seq ID No: 2);
- Figure 2 - shows the results of the analysis of purified R21 particles by transmission electron microscopy - Figure 2A.
- Figure 2B particles are shown that lack the 105 amino acid of the CS protein C terminus. The particles are negatively stained with 2% uranyl acetate;
- Figure 3 - shows the results of the analysis of R21 purified particles by reducing gel electrophoresis.
- Figure 3 A shows silver stained R21 purified particles.
- Figure 3B shows the results of a western blot using monoclonal anti-NANP antibody (from MR4, named 2A10).
- Figure 4 - shows the results of immunisation studies.
- BALB/c mice were immunised intramuscularly with 0 ⁇ g R21 with either Alhydrogel (85ug) or Abisco-100 (12ug) or AddaVax. Three shots were given 3 weeks apart and NANP-specific antibody responses were assayed by ELISA 3 weeks after each immunisation. Median responses are shown.
- Figure 5 demonstrates that R21 in Abisco adjuvant induced high titre antibodies to the NANP repeat of the CS protein but modest antibody titres to HBsAg.
- BALB/c mice were immunised intramuscularly with 5 ⁇ g R21 with Abisco- 100. Three shots were given 3 weeks apart and HBsAg-specific antibody responses were assayed by ELISA 3 weeks after the 3rd immunisation. Median responses are shown.
- Figure 6 details the results of IFN- ⁇ Spleen ELISpot analysis for BALB/c mice immunised intramuscularly with O ⁇ g R21 with either Alhydrogel (85ug) or Abisco- 100 (12ug) or AddaVax. Three shots were given 3 weeks apart and NANP-specific antibody responses were assayed by ELISA 3 weeks after each immunisation. Median responses are shown.
- FIG. 7 - demonstrates that R21 in adjuvant can be combined with viral vectors without impairing humoral immunogenicity.
- BALB/c mice were immunised with either 2 shots of R21+Abisco-100 or the ChAd63 (Ad) ME TRAP - MVA ME TRAP 8 week prime-boost regime alone or combined together, as detailed in Table 1.
- Humoral responses were assayed in the NANP ELISA carried out 3 weeks and 8 weeks after the first immunisation, and 3 weeks after the final immunisation. Median responses are shown. No impairment of the humoral immunogenicity of R21 is observed.
- FIG 8 - demonstrates that R21 in adjuvant can be combined with viral vectors without impairing T cell immunogenicity.
- BALB/c mice were immunised with either 2 shots of R21+Abisco-100 or the ChAd63 (Ad) ME TRAP - MVA ME TRAP 8 week prime-boost regime alone or combined together.
- Cellular responses were assayed in an IFN- ⁇ spleen ELISpot to a pool of CS peptides (A) or the Pb9 peptide (B) 3 weeks after the final immunisation. Median responses are shown. No impairment of the T cell immunogenicity of R21 or the viral vectors is observed.
- Figure 9 - demonstrates that mixing R21 plus adjuvants with vectors can enhance antibody responses to the vector encoded antigen.
- BALB/c mice were immunised intramuscularly with the ChAd63 (Ad) ME TRAP - MVA ME TRAP 8 week prime- boost regime alone or combined with either Abisco-100 or AddaVax.
- TRAP-specific antibody responses were assayed by ELISA 3 weeks and 8 weeks after the first immunisation and 3 weeks after the second Median responses are shown.
- FIG 10 - demonstrates that the R21 in a ISCOM adjuvant, such as Abisco or Matrix M (available from Isconova, Uppsala, Sweden) provides high level protective efficacy against malaria sporozoite infection in mice.
- the mice were infected at two immunisations with the R21 particle in adjuvant by a transgenic Plasmodium berghei parasite, transgenic for the P. falciparum CS protein gene.
- Such parasites are described in the research literature (Tewari R et al. J Biol Chem. 2002 Dec 6;277(49):47613-8; Kaba S et al. PLoS One. 2012;7(10):e48304).
- the results demonstrate that the R21 particle not only shows excellent immunogenicity against P. falciparum CS but potent efficacy in a very relevant malaria infection model.
- IM intramuscular.
- Figure 12 - demonstrates CS-specific IgG responses to R21 with different adjuvants.
- BALB/c mice were immunised intramuscularly with 0.5ug R21 alone or formulated with Alhydrogel or Abisco- 100. Three immunisations were given three weeks apart and the NANP-specific antibody titres were measured by ELISA 3 weeks after each immunisation. Median responses are shown.
- FIG. 13 - demonstrates IFN- ⁇ Spleen ELISpot responses to R21 with Matrix M.
- BALB/c mice were immunised intramuscularly with 0.5 ⁇ g R21 with Matrix M (12ug). Three shots were given 3 weeks apart and CS-specific T cell responses were measured in the spleen by IFN- ⁇ ELISpot 3 weeks after the final immunisation. Median responses are shown.
- FIG 14 - illustrates the study design for a vaccine immunisation interval study.
- the illustrated vaccine regimens were used to assess the immunogenicity of R21 + Matrix M in BALB/c mice
- Figure 15 - demonstrates CS-Specific IgG responses to R21 and Matrix M.
- BALB/c mice were immunised intramuscularly with O ⁇ g R21 with Matrix M (12ug).
- NANP-specific antibody titres were assayed by ELISA 3 weeks after each immunisation. Median responses are shown.
- FIG 16 - demonstrates IFN- ⁇ Spleen ELISpot responses to R21 and Matrix M.
- BALB/c mice were immunised intramuscularly with 0.5 ⁇ g R21 with Matrix M (12ug). Three shots were given 3 weeks apart and CS-specific T cell responses were measured in the spleen by IFNg ELISpot 3 weeks after the final immunisation. Median responses are shown.
- Figure 17 - shows the study design used to compare R21 and the CSP recombinant protein
- Figure 18 - demonstrates CS-specific IgG responses to R21 or CSP with either Matrix
- mice were immunised intramuscularly with O ⁇ g R21 or CSP with either Matrix M, MF59 or L-ASOl .
- FIG 19 - demonstrates CS-specific T cells to R21 or CSP with either Matrix M, MF59 or L-ASOl .
- CS-specific T cells BALB/c mice were immunised intramuscularly with O ⁇ g R21 or CSP with either Matrix M, MF59 or L-ASOl .
- CS specific T cell responses were measured in the blood by ICS and flow cytometry, 2 weeks after the boost vaccination.
- Isolated PBMC's were re-stimulated with a pool of CS peptides and frequencies of cytokine secreting CD4+ T cells were measured (IFNg, TNF and IL2). Mean responses shown.
- Figure 20 - illustrates an R21 vs CSP challenge experiment.
- mice were immunised intramuscularly with two shots of 0 ⁇ g R21 or CSP with Matrix M, 8 weeks apart.
- B) NANP- specific antibody titres were assayed by ELISA 3 weeks after each immunisation. Mean responses with SD are shown (Groups compared by One-way ANOVA with Bonferroni's post-test. **p ⁇ 0.01, ***p ⁇ 0.001).
- T cell responses were measured in the blood by ICS and flow cytometry, 2 weeks after the boost vaccination. Isolated PBMC's were re-stimulated with a pool of CS peptides and frequencies of cytokine secreting CD4+ T cells were measured secreting (IFNg, TNF and IL2). Mean responses with SEM are shown.
- Figure 21 - demonstrates the enhanced efficacy of combined immunisation with R21 and viral vectors.
- BALB/c mice were immunised intramuscularly with R21 + MF59 or the ChAd63 PbTRAP-MVA PbTRAP regimen alone (A or B) or combined together (C and D).
- Mice were challenged 3 weeks after boost with 1000 sporozoites injected i.v. and time to 1% parasitemia was determined by thin film blood smear from day 5 post challenge. Mice were sterilely protected if they had no blood stage parasites by day 14. Survival curves were compared by Log-rank (Mantel-Cox) Test.
- Figure 22 - demonstrates the efficacy of IgG passive transfer.
- BALB/c mice were immunised intramuscularly with R21 + Matrix M twice, 8 weeks apart, mice were bled and total IgG was purified.
- Naive mice were immunised with either B) 150ug C) 750ug or D) 1.5mg of total IgG from vaccinated mice i.v.
- a control group also received IgG from unvaccinated mice A). All mice were challenged 5 hours after IgG transfer with 1000 sporozoites injected i.v. and time to 1% parasitemia was determined by thin film blood smear from day 5 post challenge. Mice were sterilely protected if they had no blood stage parasites by day 14. Survival curves were compared by Log-rank (Mantel- Cox) Test.
- Figure 23 - demonstrates that NANP-specific IgG correlates with efficacy.
- Groups of BALB/c mice received increasing doses of total IgG from vaccinated mice (R21 + Matrix M) and had moderate - good levels of NANP-specific IgG titres at the time of challenge (A).
- particles comprising the fusion protein R21 (Seq ID no: 1, Figure 1) were produced and their immunogenic properties were considered.
- the Pv21 protein comprises the Hepatitis B surface antigen (HBsAg) adw serotype and a C- terminal portion of the circumsporozoite (CS) protein of the Plasmodium falciparum strain NF54.
- the sequence comprises 410 amino acids from N to C terminus: 75 amino acids of the NANP repeat from the CS protein - comprising MDP followed by 18 NANP repeats:
- ANPNANPNANPNANPNANPNANPN (SEQ ID NO: 3) 105 amino acid of the CS protein C terminus:
- NKNNQGNGQGHNMPNDPNRNVDENANANSAVKNNNNEEPSDKHIKEYLNKIQNSLST EWSPCSVTCGNGIQVRIKPGSANKPKDELDYANDIEKKICKMEKCSSV (SEQ ID NO: 4) (The 10 C terminal amino acids (FNVVNSSIGL) of the CS protein have been removed.) 4 amino acids from the pre-S2 region of the hepatitis B virus:
- PVTN followed by 226 amino acids of the HBsAg adw serotype:
- PichiaPinkTM Strain 4 (Invitrogen, Cat. no.Al 1150), which is a double knock-out for proteinases A and B (i.e. pep4 and prbl), was transformed by electroporation with the pPink-HC expression plasmid encoding R21. Positively transformed colonies were selected by growth on adenine deficient agar plates.
- Pv21 expressing clone was selected and grown in a 1 L batch culture with BMGY (Buffered complex medium containing glycerol). R21 expression was induced by the addition of methanol by changing the media to BMMY (Buffered complex medium containing methanol). Expression was induced with 0.5% methanol for 3 days at which point the yeast was pelleted by centrifugation at 1,500 x g for 5 minutes, the supernatant removed and the yeast frozen at -80°C.
- BMGY Buffered complex medium containing glycerol
- Yeast pellets were thawed on ice and resuspended in a lysis buffer containing lOmM Tris (pH 7.8), 0.1%Triton X-100, ImM EDTA. Acid washed glass beads (0.425-600um) were added and the sample was disrupted by 10 cycles of vortexing for one minute then placing on ice for one minute. Purification
- the clarified lysate was then layered onto a discontinuous CsCl gradient containing layers of 1.3g/ml CsCl and l . lg/ml CsCl. After ultracentrifugation for 2 hours at 41,000rpm in a SW41 Ti rotor, (Beckman Coulter Optima L-100 XP) the particle containing fraction was collected. Gel filtration
- the particle containing fraction was then applied to a PD10 column containing Sephedex G100.
- the sample was eluted in lOmM Tris (pH7.8) and particle containing fractions were collected and pooled.
- the pooled sample was then added to an isopycnic CsCl gradient containing 1.2g/ml CsCl. After ultracentrifugation for 20 hours at 41,000rpm in a SW41 Ti rotor, (Beckman Coulter Optima L-100 XP) the particle containing fraction was collected.
- the sample was then applied to a Hiprep 16/60 Sephacryl S-500 HR gel filtration column (GE Healthcare) to exchange the buffer and remove any remaining lower molecular weight contaminants.
- the sample was eluted in lOmM Tris buffer (pH7.8) and pure particle containing fractions were pooled.
- the purified R21 particle preparation was analysed by negative staining with 2% uranyl acetate on a transmission electron microscope (Figure 2A). Particles appear to be approximately 22nm in size.
- the purified R21 particle preparation was analysed by reducing gel electrophoresis.
- the sample was silver stained to assess the purity and analysed by western blotting with a monoclonal anti- NANP antibody (MR4, 2A10) and an anti-HBsAg monoclonal antibody to assess the immunoreactivity of the product.
- MR4, 2A10 monoclonal anti- NANP antibody
- anti-HBsAg monoclonal antibody to assess the immunoreactivity of the product.
- the same band was recognised by both antibodies and the purified product was greater than 90% pure based on the silver stained gel ( Figure 3).
- the presence and accessibility of the NANP repeat region on the surface of the particle was assessed by sandwich ELISA using two antibodies to the NANP repeat region. Maxisorb 96 well plates (Nunc) were coated with mouse monoclonal anti-NANP antibody (MR4, 2A10), incubated with purified R21 particle and a rabbit polyclonal serum (MR4, MRA-24) was used for detection. The purified R21 particle prep gave a strong positive signal.
- the presence and accessibility of the HBsAg portion of fusion protein in the particle was assessed by sandwich ELISA using a monoclonal antibody to the NANP repeat region (MR4, 2A10) and a cocktail of antibodies to the HBsAg from Monolisa ULTRA HBsAg ELISA kit (Biorad).
- the purified R21 particle prep gave a weak positive signal thus confirming the presence and accessibility of the HBsAg epitopes on the same NANP containing R21 particles.
- the purified particle prep is quantified by measuring absorbance at 280nm.
- Immunogenicity was assessed in mice by measuring the antibodies generated to the NANP repeat in an ELISA and by measuring T cells specific for a pool of CS peptides contained within the R21 vaccine by IFN- ⁇ spleen ELISpot. The antibody response to the HBsAg was also assessed in an ELISA.
- NANP 6 C peptide consists of 6 copies of the NANP repeat followed by a C. Maxisorb. 96 well plates (Nunc) were coated with this antigen and incubated with serum samples using a 3 fold serial dilution starting at a dilution of 1 : 1000.
- Mouse antibodies were detected with alkaline phosphatase conjugated anti-mouse IgG and pNPP (p-Nitrophenyl Phosphate, Disodium Salt) substrate and absorbance read at 405nm. The results are expressed as endpoint titre which is defined as the dilution at which the OD of the sample is equal to background.
- the R21 particle vaccine was found to be highly immunogenic in mice and there is a notable boost effect after each vaccination (Figure 4.). Furthermore, if R21 is administered with the adjuvant Abisco or AddaVax slightly higher antibody titres were induced as compared to R21 administered with Alhydrogel.
- T cells induced by immunisation with R21 were measured using IFN- ⁇ ELISpot assay. Fresh splenocytes were isolated and incubated in duplicate wells for 20 hours. Cells were restimulated with a pool of CS peptides spanning the entire CS protein at a final concentration of 2ug/ml.
- T cell responses were only measured after the third vaccination.
- R21 administered with Abisco is more effective at inducing T cells to the CS peptides in mice than R21 administered with Ahydrogel.
- Anti-HBsAg antibody ELISA is more effective at inducing T cells to the CS peptides in mice than R21 administered with Ahydrogel.
- Anti-HBsAg antibody ELISA is more effective at inducing T cells to the CS peptides in mice than R21 administered with Ahydrogel.
- Anti-HBsAg antibodies induced by R21 immunisation with Abisco adjuvant were assessed in an ELISA using HBsAg particle.
- the HBsAg particle was coated onto maxisorb 96 well plates (Nunc) and the plates were incubated with serum samples using a 3 fold serial dilution starting at a dilution of 1 : 100.
- Mouse IgG antibodies were detected and the results expressed as for the anti-NANP antibody ELISA above.
- HBsAg antibodies were assessed after three immunisations. Low antibody titres to the HBsAg were detected in all of the immunised mice in contrast to high titre antibodies against NANP ( Figure 5). This result shows that the R21 particle induces preferentially antibodies to the malaria rather than the hepatitis B component of R21.
- a combination of R21, or a similar RTS or RTS,S like particle, plus a saponin containing adjuvant such as Abisco, matrix M, QS21, AS01 or AS02, plus MVA encoding TRAP or ME TRAP were identified as a novel and particularly preferred vaccine combination for malaria.
- Figures 7 and 8 show that this combination allows both exceptionally high antibody titres (to CSP) and T cell responses to TRAP to be attained. As these are arguably the best characterised correlates of protective immunity to pre-erythrocytic malaria in humans the use of this combination vaccine for boosting malaria immunity should be particularly effective.
- MVA is a vector that allows multiple antigens to be expressed so the MVA expressing TRAP in this mixture may also express another malaria antigens, such as for example CSP, from the same or another MVA locus, or may even express an antigen from another pathogen, such as antigen 85A from Mycobacterium tuberculosis.
- R21 or a similar particle such as RTS or RTS,S
- a saponin adjuvant such as matrix M or Iscomatrix or AS01 or AS02
- an emulsion adjuvant such as Addavax or MF59
- Vaccine regimens used to assess the immunogenicity of R21 + adjuvant or ChAd63 ME TRAP - MVA ME TRAP in BALB/c mice administered alone or in combination. Combination vaccines formulated together and administered in the same syringe.
- Anti-TRAP antibodies induced by viral vector immunisation were assessed in an ELISA using TRAP recombinant protein.
- the TRAP protein was coated onto maxisorb 96 well plates (Nunc) and the plates were incubated with serum samples using a 3 fold serial dilution starting at a dilution of 1 : 100.
- Mouse IgG antibodies were detected and the results expressed as for the anti- NANP antibody ELISA above.
- R21 can be administered in a number of regimens for optimal immunogenicity
- Immunisation with R21 in a range of adjuvants induces higher antibody titres and CS-specific T cells than CSP recombinant protein.
- a study recently compared four CSP protein vaccines head to head to determine which elicited the highest immune responses and superior efficacy.
- the most immunogenic recombinant protein evaluated was produced in E.coli by Gennova (Pune, India) and this was obtained from PATH Malaria Vaccine Initiative (MVI, Washington DC) for assessment against R21. This assessment was performed with 3 different adjuvants Matrix M (similar to Abisco-100), MF59 (similar to AddaVax) and a biosimilar of the proprietary GSK adjuvant AS01, obtained from Lausanne here called L-AS01.
- R21 is more efficacious than CSP recombinant protein
- R21 is not only more immunogenic but also more efficacious than CSP recombinant protein.
- Mice were immunised with R21 or CSP formulated with Matrix M and challenged with transgenic parasites (P.berghei transgenic for P. falciparum CSP) 3 weeks after boost.
- R21 + Matrix M protected 87.5% of the vaccinated mice and CSP + Matrix M protected only 42.5% ( Figure 20-A).
- the levels of both CS-specific antibodies and T cells were also higher in the R21 + Matrix M groups ( Figure 20-B+C).
- Group 1 was immunised with 0.5 micrograms of R21 in Abisco adjuvant intramuscularly, twice with an eight-week interval.
- Group 2 received the same dose of R21 with the very similar matrix M adjuvant (also supplied by Isconova, Uppsala, Sweden) with the same interval; the Matrix M is suitable for clinical use.
- Group 3 received a single dose of 1 x 108 ifu of a chimpanzee adenovirus (ChAd63) expressing the CS gene followed 8 weeks later by a single dose of 1x106 pfu of an MVA vector expressing the CS gene, both by the intramuscular route.
- ChAd63 chimpanzee adenovirus
- Group 4 were immunised with adjuvant only twice with an 8 week interval, 5 mice receiving Abisco and 5 receiving Matrix M. Three weeks after the day of the booster immunisation all mice were infected by a 1000 sporozoites intravenously of a P. berghei parasite transgenic for the circumsporozoite gene of P. falciparum. Mice were scored for time to 1% parasitaemia by microscopy. 10/10 control adjuvant only mice were infected; 6/8 from Group 3 were infected showing modest efficacy with the vectored vaccines. In contrast only 1/16 mice in Groups 1 and 2 were infected showing 94% sterile efficacy with R21 with the ISCOM adjuvant formulations.
- Vaccine efficacy is enhanced by combining R21 and viral vectors
- mice receiving a passive transfer of increasing doses of total IgG from mice immunised with R21 + Matrix M were protected against sporozoite challenge in a dose dependant manner (Figure 22).
- NANP-specific IgG titres were measured 1 day after challenge ( Figure 23 -A) and mice had good to moderate titres that correlated with the efficacy measured as delay to 1% parasitemia ( Figure 23 -B).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1301022.8A GB201301022D0 (en) | 2013-01-22 | 2013-01-22 | Composition and uses thereof |
GB201308242A GB201308242D0 (en) | 2013-05-08 | 2013-05-08 | Compositions and uses thereof |
PCT/GB2014/050156 WO2014111733A1 (en) | 2013-01-21 | 2014-01-21 | Composition and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2945649A1 true EP2945649A1 (en) | 2015-11-25 |
EP2945649B1 EP2945649B1 (en) | 2018-12-12 |
Family
ID=50190474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14707429.8A Active EP2945649B1 (en) | 2013-01-22 | 2014-01-21 | Composition and uses thereof |
Country Status (3)
Country | Link |
---|---|
US (2) | US9821046B2 (en) |
EP (1) | EP2945649B1 (en) |
WO (1) | WO2014111733A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100068390A (en) * | 2007-08-13 | 2010-06-23 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Vaccines |
AU2017206102C1 (en) | 2016-01-08 | 2022-02-10 | Geovax Inc. | Compositions and methods for generating an immune response to a tumor associated antigen |
GB201608821D0 (en) | 2016-05-19 | 2016-07-06 | Isis Innovation | Vaccines |
WO2019021013A1 (en) * | 2017-07-27 | 2019-01-31 | Oxford University Innovation Limited | Malaria vaccine |
US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
WO2023076907A1 (en) * | 2021-10-25 | 2023-05-04 | Novavax AB | Malaria vaccine formulations |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0614465T3 (en) | 1991-11-16 | 1999-09-27 | Smithkline Beecham Biolog | Hybrid protein between CS from Plasmodium and HBsAg |
WO2004110482A1 (en) | 2003-06-13 | 2004-12-23 | Isis Innovation Limited | Improved vaccines |
BRPI0715581A2 (en) * | 2006-07-18 | 2013-04-24 | Glaxosmithkline Biolog Sa | immunogenic hybrid fusion protein, composition, use of a protein or particle, method for treating a patient susceptible to plasmid infection, nucleotide sequence, host, and process for protein production |
-
2014
- 2014-01-21 WO PCT/GB2014/050156 patent/WO2014111733A1/en active Application Filing
- 2014-01-21 EP EP14707429.8A patent/EP2945649B1/en active Active
- 2014-01-21 US US14/762,106 patent/US9821046B2/en active Active
-
2017
- 2017-10-18 US US15/787,368 patent/US20180028635A1/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
None * |
See also references of WO2014111733A1 * |
Also Published As
Publication number | Publication date |
---|---|
US20180028635A1 (en) | 2018-02-01 |
EP2945649B1 (en) | 2018-12-12 |
WO2014111733A1 (en) | 2014-07-24 |
US20160144011A1 (en) | 2016-05-26 |
US9821046B2 (en) | 2017-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180028635A1 (en) | Composition and uses thereof | |
EP1896060B1 (en) | Anti-malaria vaccine | |
JP3954643B2 (en) | Hybrid protein between CS and HBsAG derived from Plasmodium | |
JP2008516926A (en) | Malaria primary immunization / boost vaccine | |
JP2012508160A (en) | Vaccine composition | |
JP2021506767A (en) | Hepatitis B immunization regimen and composition | |
KR20100109556A (en) | Vaccines for malaria | |
AU2011310838B2 (en) | Heterologous prime boost vaccination regimen against malaria | |
US20200207811A1 (en) | Malaria vaccine | |
WO2013082500A2 (en) | Vaccine for falciparum malaria | |
JP2021506771A (en) | Hepatitis B immunization regimen and composition | |
JP2011507817A (en) | Malaria vaccine | |
US11344614B2 (en) | Pharmaceutical compositions comprising dengue virus-specific multiple HLA-binding T cell epitopes | |
RU2362586C2 (en) | Pharmaceutical compositions for therapeutic application | |
OA20058A (en) | Malaria vaccine. | |
KR20240099337A (en) | Malaria vaccine formulation | |
WO2015091734A1 (en) | Novel malaria vaccines | |
WO2014188212A2 (en) | Treatment and prevention of malaria | |
BR102022005915A2 (en) | PROCESS FOR PRODUCING AND PURIFYING A RECOMBINANT PROTEIN, RECOMBINANT PROTEIN, USE OF THE RECOMBINANT PROTEIN, IMMUNOBIOLOGICAL COMPOSITION, AND USE OF THE IMMUNOBIOLOGICAL COMPOSITION | |
AU2022379612A1 (en) | Malaria vaccine formulations | |
Moulton | An Improved Manufacturing Process for a Recombinant Polyprotein Vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20150818 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: OXFORD UNIVERSITY INNOVATION LIMITED |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: OXFORD UNIVERSITY INNOVATION LIMITED |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20170406 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 38/16 20060101ALI20180726BHEP Ipc: A61K 39/015 20060101AFI20180726BHEP Ipc: A61K 39/12 20060101ALI20180726BHEP Ipc: C07K 14/445 20060101ALI20180726BHEP |
|
INTG | Intention to grant announced |
Effective date: 20180816 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1075100 Country of ref document: AT Kind code of ref document: T Effective date: 20181215 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602014037790 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: VALIPAT S.A. GEVERS SA, CH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: RUE DES NOYERS 11, 2000 NEUCHATEL (CH) |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190312 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190312 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1075100 Country of ref document: AT Kind code of ref document: T Effective date: 20181212 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190313 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190412 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190412 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602014037790 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190121 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 |
|
26N | No opposition filed |
Effective date: 20190913 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20140121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230526 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20240123 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20240118 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240119 Year of fee payment: 11 Ref country code: GB Payment date: 20240116 Year of fee payment: 11 Ref country code: CH Payment date: 20240201 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240118 Year of fee payment: 11 Ref country code: BE Payment date: 20240122 Year of fee payment: 11 |